Transgene S.a.

Institut Pasteur

Transgene

Transgene S.a., Institut Pasteur

Transgene S.a. and Institute Pasteur

Marie-Paule Kieny

Richard Lathe

Jean-Marc Balloul

Jean-Pierre Lecocq

Nadine Bizouarne

Luc Montagnier

Pierre H Chambon

Marc Girard

Guy Rautmann

Mara Hareuveni

Simon Wain Hobson

Robert Drillien

Guerrino Meneguzzi

Gerard Loison

Andre Capron

Jean-Marie Grzych

Raymond Pierce

Paul Sondermeyer

A pharmaceutical composition for treating or preventing a papillomavirus infection or tumor, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.

Pharmaceutical compositions for treating papillomavirus tumors and infection

A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined-with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.

Antitumoral compositions can comprise as therapeutic agent one or several immunogenic polypeptides, of which at least one is modified so as to have a cell location different from its native location. Compositions can be based on a recombinant vector expressing such an immunogenic polypeptide. A recombinant vector comprising at least the sequences coding for an immunogenic polypeptide originating from a precocious and/or tardive region of a papillomavirus having a modified location and a viral particle comprising said vector is also described. Finally, therapeutic uses of such a composition, such a recombinant vector and such a viral particle are described.

Antitumoral composition based on immunogenic polypeptide with modified cell location

A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.

Pharmaceutical composition for treating papillomavirus tumors and infection

Antitumoral compositions can comprise as therapeutic agent one or several immunogenic polypeptides, of which at least one is modified so as to have a cell location different from its native location. Compositions can be based on a recombinant vector expressing such an immunogenic polypeptide. A recombinant vector comprising at least the sequences coding for an immunogenic polypeptide originating from a precocious and/or tardive region of a papillomavirus having a modified location and a viral particle comprising the vector is also described. Finally, therapeutic uses of such a composition, such a recombinant vector and such a viral particle are described.

Pharmaceutical compositions are disclosed which comprise recombinant viruses containing a DNA fragment encoding a polypeptide recognized by a particular antibody H23, which recognizes a particular tumor antigen expressed on breast cancer cells. This antibody specifically binds to an epitope comprising a tandem repeat sequence of 20 amino acids comprised in a transmembrane form as well as a secreted form of the polypeptide specifically bound by antibody H23.

Pharmaceutical composition for the treatment or prevention of a malignant tumor

Immunogenic compositions comprising soluble, non-cleavable, chimeric HIV-1 gp160 variants capable of eliciting human immunodeficiency virus type 1 (HIV-1) gp160-specific antibodies are provided. These HIV-1 gp160 variants comprise the following regions: i) a first region derived from the gp160 of a first strain of HIV-1; ii) a second region derived from the gp160 of a second strain of HIV-1 wherein said second region fails to contain functional major and minor proteolytic cleavage sites (amino acids 483-486 and 475-479, respectively) and functional major and minor hydrophobic domains (amino acids 487-516 and 659-680, respectively); and iii) an optional third region, derived from the gp160 of said second strain, located at the amino terminus of the recombinant envelope.

Immunogenic compositions comprising soluble, non-cleavable, chimeric HIV-1 gp160-variants

This invention is directed toward soluble, non-cleavable, chimeric human immunodeficiency virus type 1 (HIV-1) gp160 variants, expression vectors encoding said variants, and methods of producing said variants. These HIV-1 gp160 variants comprise the following regions: I) a first region derived from the gp160 of a first strain of HIV-1; ii) a second region derived from the gp160 of a second strain of HIV-1 wherein said second region fails to contain functional major and minor proteolytic cleavage sites (amino acids 483-486 and 475-479, respectively) and functional major and minor hydrophobic domains (amino acids 487-516 and 659-680, respectively); and iii) an optional third region, derived from the gp160 of said second strain, located at the amino terminus of the recombinant envelope.

Expression cassettes encoding soluble, non-cleavable, chimeric HIV-1 GP160 variants, their methods of construction, and methods for the production of GP160 variants

The application provides a polypeptide and a pharmaceutical composition which comprises said polypeptide, wherein said polypeptide is recognized by a particular antibody H23, which recognizes a particular tumor antigen expressed on breast cancer cells. This antibody specifically binds to an epitope comprising a tandem repeat sequence of 20 amino acids comprised in a transmembrane form as well as a secreted form of the polypeptides specifically bound by antibody H23.

The present invention relates to a vaccinia virus, characterised in that it contains all or part of a DNA sequence (I) coding for an antigenic glycoprotein of rabies.

Vaccine against rabies and process for preparation thereof

The invention concerns a vector being vaccinia virus, which comprises a heterologous DNA sequence which codes at least for the essential region of a tumor specific protein called T antigen, cloned within a non essential region of the vaccinia virus, as well as regulatory element required for the expression of the DNA sequence in higher cells, the vector is particularly useful as a pharmaceutical composition having a preventive or creative activity against tumors especially tumors caused by a papillomavirus.

Expression of a tumor-specific antigen by a recombinant vector virus and

A pharmaceutical composition which comprises a recombinant vaccinia virus containing a DNA fragment encoding for a polypeptide recognized by a particular antibody H23, which recognizes a particular tumor antigen expressed on breast cancer cells is provided. The antibody specifically binds to an epitope comprising a tandem repeat sequence of 20 amino acids comprised in a transmembrane form as well as a secreted form of the POLYPEPTIDES specifically bound by antibody H23.

Pharmaceutical composition for the treatment of a malignant tumor

The present invention relates to a vaccinia virus, characterized in that it contains all or part of a DNA sequence (I) coding for an antigenic glycoprotein of rabies.

This invention relates to an immunogenic composition comprising a viral vector. The genome of the viral vector comprises a functional origin of replication of a poxvirus, a DNA fragment encoding a non-cleavable gp160, a DNA fragment encoding a signal peptide, and a promoter for expressing DNA fragments in mammalian cells.

Viral vector coding for a glycoprotein of the virus responsible for

The invention concerns a vector being vaccinia virus, which comprises a heterologous DNA sequence which codes at least for the essential region of a tumor specific protein called T antigen, cloned within a non essential region of the vaccinia virus, as well as regulatory element required for the expression of said DNA sequence in higher cells, the vector is particularly useful as a pharmaceutical composition having a preventive or creative activity against tumors especially tumors caused by a papillomavirus.

Growing community of inventors

Strasbourg, France

Marie-Paule Kieny